Litcius/Paper detail

99mTc-labeled iRGD for single-positron emission computed tomography imaging of triple-negative breast cancer

Buhui Yu, Hongxing Su, Lingzhou Zhao, Jiqin Yang, Meilin Zhu, Jinhua Zhao

2022Frontiers in Bioengineering and Biotechnology13 citationsDOIOpen Access PDF

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, with a high mortality rate. One of the main reasons for this poor prognosis is the failure of a specific diagnosis. As a tumor-homing and penetrating peptide, iRGD has not only the properties of binding to neuropilin-1 and integrin αvβ3 but also internalizing into TNBC cells. In this study, we designed and prepared 99m Tc-labeled iRGD ( 99m Tc-HYNIC-iRGD) as a single-positron emission computed tomography (SPECT) imaging probe and investigated its feasibility for the targeted diagnosis of TNBC. The results showed that the iRGD peptide had acceptable biocompatibility within the studied concentration range and could specifically bind to TNBC cells in vitro . The 99m Tc-HYNIC-iRGD was readily prepared with high radiochemical purity and stability. SPECT imaging of 99m Tc-HYNIC-iRGD in a TNBC tumor-bearing mouse model showed obvious tumor accumulation with rapid blood clearance and favorable biodistribution. Our findings indicate that this active-targeted strategy has great potential to be developed as a novel tool for TNBC imaging.

Topics & Concepts

Triple-negative breast cancerPositron emission tomographyBiodistributionBreast cancerCancer researchNeuropilin 1Nuclear medicineIn vitroSpect imagingEmission computed tomographyMedicineChemistryCancerInternal medicineBiochemistryVEGF receptorsVascular endothelial growth factorCell Adhesion Molecules ResearchRadiopharmaceutical Chemistry and ApplicationsMonoclonal and Polyclonal Antibodies Research